In a recent study of patients with NSCLC receiving chemoimmunotherapy, an approach typically restricted to those with PDL1 expression < 50% in our practice, patients with mild irAEs demonstrated improved PFS and OS compared to patients with severe or no irAEs [8]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.